Cargando…

Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions

Alcohol and other substance use disorders share comorbidity with other RDS disorders, i.e., a reduction in dopamine signaling within the reward pathway. RDS is a term that connects addictive, obsessive, compulsive, and impulsive behavioral disorders. An estimated 2 million individuals in the United...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blum, Kenneth, Bowirrat, Abdalla, Braverman, Eric R., Baron, David, Cadet, Jean Lud, Kazmi, Shan, Elman, Igor, Thanos, Panyotis K., Badgaiyan, Rajendra D., Downs, William B., Bagchi, Debasis, Llanos-Gomez, Luis, Gold, Mark S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582845/ https://www.ncbi.nlm.nih.gov/pubmed/34770047 http://dx.doi.org/10.3390/ijerph182111529

Ejemplares similares

Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It “Blowin’ in the Wind”?
por: Blum, Kenneth, et al.
Publicado: (2022)

Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?
por: Blum, Kenneth, et al.
Publicado: (2022)

Hypothesizing That Pediatric Autoimmune Neuropsychiatric Associated Streptococcal (PANDAS) Causes Rapid Onset of Reward Deficiency Syndrome (RDS) Behaviors and May Require Induction of “Dopamine Homeostasis”
por: Blum, Kenneth, et al.
Publicado: (2022)

Genetic Addiction Risk Severity Assessment Identifies Polymorphic Reward Genes as Antecedents to Reward Deficiency Syndrome (RDS) Hypodopaminergia’s Effect on Addictive and Non-Addictive Behaviors in a Nuclear Family
por: Dennen, Catherine A., et al.
Publicado: (2022)

Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence?
por: Madigan, Margaret A., et al.
Publicado: (2022)

Evidence for the DRD2 Gene as a Determinant of Reward Deficiency Syndrome (RDS)
por: Blum, Kenneth, et al.
Publicado: (2023)

DNA Directed Pro-Dopamine Regulation Coupling Subluxation Repair, H-Wave(®) and Other Neurobiologically Based Modalities to Address Complexities of Chronic Pain in a Female Diagnosed with Reward Deficiency Syndrome (RDS): Emergence of Induction of “Dopamine Homeostasis” in the Face of the Opioid Crisis
por: Bajaj, Anish, et al.
Publicado: (2022)

A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing “Precision Behavioral Management”
por: Blum, Kenneth, et al.
Publicado: (2021)

Theorizing the Role of Dopaminergic Polymorphic Risk Alleles with Intermittent Explosive Disorder (IED), Violent/Aggressive Behavior and Addiction: Justification of Genetic Addiction Risk Severity (GARS) Testing
por: Modestino, Edward Justin, et al.
Publicado: (2022)

Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case–Control Subjects
por: Blum, Kenneth, et al.
Publicado: (2022)

Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?
por: Blum, Kenneth, et al.
Publicado: (2021)

Pro-Dopamine Regulator – (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS)
por: Blum, Kenneth, et al.
Publicado: (2017)

A Novel Precision Approach to Overcome the “Addiction Pandemic” by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration
por: Blum, Kenneth, et al.
Publicado: (2021)

Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction
por: Blum, Kenneth, et al.
Publicado: (2015)

“TO BE OR NOT TO BE” GWAS Ends the Controversy about the DRD2 Gene as a Determinant of Reward Deficiency Syndrome (RDS)
por: Blum, Kenneth, et al.
Publicado: (2023)

Genetic Addiction Risk and Psychological Profiling Analyses for “Preaddiction” Severity Index
por: Blum, Kenneth, et al.
Publicado: (2022)

Invited Expert Opinion- Bioinformatic and Limitation Directives to Help Adopt Genetic Addiction Risk Screening and Identify Preaddictive Reward Dysregulation: Required Analytic Evidence to Induce Dopamine Homeostatsis
por: Blum, Kenneth, et al.
Publicado: (2023)

Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine Regulation
por: Blum, Kenneth, et al.
Publicado: (2022)

Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated)
por: Kenneth, Blum, et al.
Publicado: (2018)

Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids
por: Ceccanti, Mauro, et al.
Publicado: (2022)

Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms
por: Blum, Kenneth, et al.
Publicado: (2015)

Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape
por: Blum, Kenneth, et al.
Publicado: (2017)

How to Combat the Global Opioid Crisis
por: Dennen A., Catherine, et al.
Publicado: (2023)

Beyond Mor: Can Induction of Dopamine Homeostasis Along with Electrotherapy Attenuate the Opioid Crisis?
por: Blum, Kenneth, et al.
Publicado: (2023)

Proposing a “Brain Health Checkup (BHC)” as a Global Potential “Standard of Care” to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of “Dopamine Homeostasis”
por: Braverman, Eric R., et al.
Publicado: (2022)

Induction of homeostatic biological parameters in reward deficiency as a function of an iron-free multi-nutrient complex: Promoting hemoglobinization, aerobic metabolism, viral immuno-competence, and neuroinflammatory regulation
por: Blum, Kenneth, et al.
Publicado: (2020)

Generational Association Studies of Dopaminergic Genes in Reward Deficiency Syndrome (RDS) Subjects: Selecting Appropriate Phenotypes for Reward Dependence Behaviors
por: Blum, Kenneth, et al.
Publicado: (2011)

Neurogenetics and Epigenetics of Loneliness
por: Bowirrat, Abdalla, et al.
Publicado: (2023)

Offering a putative neurobiological “dopamine homeostatic” solution to overcome the perils of the reward deficiency syndrome pandemic: emergence of “precision behavioral management”
por: Blum, Kenneth, et al.
Publicado: (2022)

Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors
por: Blum, Kenneth, et al.
Publicado: (2018)

Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?
por: Blum, Kenneth, et al.
Publicado: (2015)

Calvin klein (CK) designer cocktail, new “Speedball” is the “grimm reaper”: Brain dopaminergic surge a potential death sentence
por: Gold, Mark S, et al.
Publicado: (2020)

Opioid and dopamine genes interact to predict precision naltrexone response in alcohol use disorder: Interpretation misfires
por: Blum, Kenneth, et al.
Publicado: (2021)

“Preaddiction” construct and reward deficiency syndrome: genetic link via dopaminergic dysregulation
por: Blum, Kenneth, et al.
Publicado: (2022)

Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors
por: Gupta, Ashim, et al.
Publicado: (2022)

Neurogenetic and Epigenetic Aspects of Cannabinoids
por: Dennen, Catherine A., et al.
Publicado: (2022)

Can We Combat Reward Deficiency Behaviors (RDS) including Substance Use Disorder (SUD) through Genetic Risk Screening coupled with Precision Pro-Dopamine Regulation by Algorithmic matched Polymorphic Allelic Risks
por: Blum, Kenneth, et al.
Publicado: (2019)

Positive Clinical Outcomes for Severe Reported Pain Using Robust Non-Addictive Home Electrotherapy—A Case-Series
por: Bajaj, Anish, et al.
Publicado: (2023)

Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?
por: Gold, Mark S., et al.
Publicado: (2020)

Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary
por: Blum, Kenneth, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_7vm4lvg9287r94sminjcsfhsqd